دورية أكاديمية
Theranostics Using Antibodies and Antibody-Related Therapeutics.
| العنوان: | Theranostics Using Antibodies and Antibody-Related Therapeutics. |
|---|---|
| المؤلفون: | Moek KL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Giesen D; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Kok IC; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., de Groot DJA; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Jalving M; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Fehrmann RSN; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Lub-de Hooge MN; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and., Brouwers AH; Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands e.g.e.de.vries@umcg.nl. |
| المصدر: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 Sep; Vol. 58 (Suppl 2), pp. 83S-90S. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Reston, VA : Society of Nuclear Medicine Original Publication: [Chicago, Ill.] : S.N. Turiel & Assoc. |
| مواضيع طبية MeSH: | Diagnostic Techniques and Procedures*, Immunoconjugates/*therapeutic use, Animals ; Humans ; Immunotherapy ; Isotope Labeling ; Molecular Imaging |
| مستخلص: | In theranostics, radiolabeled compounds are used to determine a treatment strategy by combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) and antibody-related therapeutics represent a rapidly expanding group of cancer medicines. Theranostic approaches using these drugs in oncology are particularly interesting because antibodies are designed against specific targets on the tumor cell membrane and immune cells as well as targets in the tumor microenvironment. In addition, these drugs are relatively easy to radiolabel. Noninvasive molecular imaging techniques, such as SPECT and PET, provide information on the whole-body distribution of radiolabeled mAbs and antibody-related therapeutics. Molecular antibody imaging can potentially elucidate drug target expression, tracer uptake in the tumor, tumor saturation, and heterogeneity for these parameters within the tumor. These data can support drug development and may aid in patient stratification and monitoring of the treatment response. Selecting a radionuclide for theranostic purposes generally starts by matching the serum half-life of the mAb or antibody-related therapeutic and the physical half-life of the radionuclide. Furthermore, PET imaging allows better quantification than the SPECT technique. This information has increased interest in theranostics using PET radionuclides with a relatively long physical half-life, such as 89 Zr. In this review, we provide an overview of ongoing research on mAbs and antibody-related theranostics in preclinical and clinical oncologic settings. We identified 24 antibodies or antibody-related therapeutics labeled with PET radionuclides for theranostic purposes in patients. For this approach to become integrated in standard care, further standardization with respect to the procedures involved is required. (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.) |
| فهرسة مساهمة: | Keywords: PET; cancer; molecular imaging; monoclonal antibodies; oncology; theranostics |
| المشرفين على المادة: | 0 (Immunoconjugates) |
| تواريخ الأحداث: | Date Created: 20170903 Date Completed: 20170925 Latest Revision: 20181219 |
| رمز التحديث: | 20221213 |
| DOI: | 10.2967/jnumed.116.186940 |
| PMID: | 28864618 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1535-5667 |
|---|---|
| DOI: | 10.2967/jnumed.116.186940 |